Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02785250
Title Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors ImmunoVaccine Technologies, Inc.

fallopian tube cancer

ovary epithelial cancer

peritoneum cancer


Cyclophosphamide + DPX-Survivac + Epacadostat

Age Groups: adult
Covered Countries USA | CAN

No variant requirements are available.